Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| cardiac muscle cell | 7 studies | 67% ± 20% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| heart | 5 studies | 29% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| muscle | 100% | 15410.60 | 803 / 803 | 0% | 0 | 0 / 0 |
| heart | 100% | 41462.81 | 860 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 65% | 1434.61 | 869 / 1335 | 0% | 0 | 0 / 0 |
| brain | 0% | 1.25 | 4 / 2642 | 45% | 1.43 | 314 / 705 |
| uterus | 17% | 78.42 | 29 / 170 | 7% | 3.06 | 34 / 459 |
| skin | 1% | 16.88 | 15 / 1809 | 21% | 2.97 | 101 / 472 |
| adrenal gland | 0% | 6.71 | 1 / 258 | 20% | 0.81 | 45 / 230 |
| prostate | 9% | 176.56 | 23 / 245 | 10% | 2.24 | 51 / 502 |
| tonsil | 0% | 0 | 0 / 0 | 16% | 2.22 | 7 / 45 |
| stomach | 4% | 19.43 | 16 / 359 | 2% | 0.05 | 6 / 286 |
| esophagus | 5% | 30.19 | 71 / 1445 | 2% | 0.05 | 3 / 183 |
| lung | 1% | 57.92 | 8 / 578 | 3% | 0.10 | 40 / 1155 |
| breast | 2% | 33.82 | 7 / 459 | 3% | 0.12 | 37 / 1118 |
| ovary | 1% | 4.79 | 2 / 180 | 3% | 0.92 | 14 / 430 |
| intestine | 2% | 8.40 | 18 / 966 | 1% | 0.05 | 3 / 527 |
| thymus | 1% | 10.03 | 5 / 653 | 1% | 0.09 | 9 / 605 |
| pancreas | 0% | 1.68 | 1 / 328 | 1% | 0.02 | 2 / 178 |
| bladder | 0% | 0 | 0 / 21 | 1% | 0.02 | 6 / 504 |
| kidney | 0% | 0 | 0 / 89 | 1% | 0.02 | 8 / 901 |
| adipose | 1% | 7.42 | 9 / 1204 | 0% | 0 | 0 / 0 |
| liver | 0% | 0 | 0 / 226 | 1% | 0.03 | 3 / 406 |
| peripheral blood | 1% | 4.25 | 6 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0045214 | Biological process | sarcomere organization |
| GO_0007519 | Biological process | skeletal muscle tissue development |
| GO_0070885 | Biological process | negative regulation of calcineurin-NFAT signaling cascade |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0008150 | Biological process | biological_process |
| GO_0043503 | Biological process | skeletal muscle fiber adaptation |
| GO_0015629 | Cellular component | actin cytoskeleton |
| GO_0030017 | Cellular component | sarcomere |
| GO_0030018 | Cellular component | Z disc |
| GO_0031433 | Molecular function | telethonin binding |
| GO_0051373 | Molecular function | FATZ binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0003779 | Molecular function | actin binding |
| GO_0030346 | Molecular function | protein phosphatase 2B binding |
| Gene name | MYOZ2 |
| Protein name | Myozenin-2 (Calsarcin-1) (FATZ-related protein 2) Myozenin 2 Alternative protein MYOZ2 |
| Synonyms | C4orf5 |
| Description | FUNCTION: Myozenins may serve as intracellular binding proteins involved in linking Z line proteins such as alpha-actinin, gamma-filamin, TCAP/telethonin, LDB3/ZASP and localizing calcineurin signaling to the sarcomere. Plays an important role in the modulation of calcineurin signaling. May play a role in myofibrillogenesis. |
| Accessions | L8E8B5 A0A1B1HY28 Q9NPC6 ENST00000307128.6 |